
Galapagos NV GLPG
$ 28.89
-0.93%
Annual report 2025
added 04-04-2026
Galapagos NV DIO Ratio 2011-2026 | GLPG
Annual DIO Ratio Galapagos NV
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 0.915 | 0.923 | 2.2 | 1.55 | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.2 | 0.915 | 1.4 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
345 | - | -24.86 % | $ 820 K | ||
|
Alnylam Pharmaceuticals
ALNY
|
43.5 | $ 322.18 | -3.36 % | $ 42.2 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | ||
|
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
166 | $ 22.0 | 1.48 % | $ 1.03 B | ||
|
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - | ||
|
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M | ||
|
Akebia Therapeutics
AKBA
|
147 | $ 1.38 | -10.97 % | $ 355 M | ||
|
Grifols, S.A.
GRFS
|
0.000171 | $ 8.6 | -1.04 % | $ 6.83 B | ||
|
Aquestive Therapeutics
AQST
|
120 | $ 4.28 | 0.94 % | $ 458 M | ||
|
Arcutis Biotherapeutics
ARQT
|
185 | $ 23.69 | -3.64 % | $ 3.01 B | ||
|
BioDelivery Sciences International
BDSI
|
321 | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
70.7 | $ 1.59 | 6.71 % | $ 423 M | ||
|
BeiGene, Ltd.
BGNE
|
304 | - | 0.49 % | $ 251 B | ||
|
Caladrius Biosciences
CLBS
|
35.8 | - | -16.75 % | $ 25.8 M |